Inhibiting the nucleo-cytoplasmic translocation of HMGB1, particularly through ICM treatment, reduces STAT3 activation and PD-L1 expression, leading to decreased tumor growth in vivo. This evidence concerns the gene HMGB1 and neoplasm.